92 related articles for article (PubMed ID: 8343170)
21. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
[TBL] [Abstract][Full Text] [Related]
22. The fate of antibodies bound to the surface of tumor cells in vitro.
Kyriakos RJ; Shih LB; Ong GL; Patel K; Goldenberg DM; Mattes MJ
Cancer Res; 1992 Feb; 52(4):835-42. PubMed ID: 1737345
[TBL] [Abstract][Full Text] [Related]
23. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26.
Blanco J; Marié I; Callebaut C; Jacotot E; Krust B; Hovanessian AG
Exp Cell Res; 1996 May; 225(1):102-11. PubMed ID: 8635502
[TBL] [Abstract][Full Text] [Related]
24. In vitro phosphorylation of human immunodeficiency virus type 1 Tat protein by protein kinase C: evidence for the phosphorylation of amino acid residue serine-46.
Holmes AM
Arch Biochem Biophys; 1996 Nov; 335(1):8-12. PubMed ID: 8914829
[TBL] [Abstract][Full Text] [Related]
25. Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides.
Anderson DC; Manger R; Schroeder J; Woodle D; Barry M; Morgan AC; Fritzberg AR
Bioconjug Chem; 1993; 4(1):10-8. PubMed ID: 8431507
[TBL] [Abstract][Full Text] [Related]
26. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
27. The interaction of HIV-1 Tat(32-72) with its target RNA: a fluorescence and nuclear magnetic resonance study.
Metzger AU; Bayer P; Willbold D; Hoffmann S; Frank RW; Goody RS; Rösch P
Biochem Biophys Res Commun; 1997 Dec; 241(1):31-6. PubMed ID: 9405229
[TBL] [Abstract][Full Text] [Related]
28. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of a dimeric RNA-peptide complex.
Campisi DM; Calabro V; Frankel AD
EMBO J; 2001 Jan; 20(1-2):178-86. PubMed ID: 11226168
[TBL] [Abstract][Full Text] [Related]
30. Proximity of a Tat peptide to the HIV-1 TAR RNA loop region determined by site-specific photo-cross-linking.
Wang Z; Huq I; Rana TM
Bioconjug Chem; 1999; 10(3):512-9. PubMed ID: 10346885
[TBL] [Abstract][Full Text] [Related]
31. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library.
Pilkington GR; Duan L; Zhu M; Keil W; Pomerantz RJ
Mol Immunol; 1996; 33(4-5):439-50. PubMed ID: 8676895
[TBL] [Abstract][Full Text] [Related]
33. The fd phage and a peptide derived from its p8 coat protein interact with the HIV-1 Tat-NLS and inhibit its biological functions.
Krichevsky A; Rusnati M; Bugatti A; Waigmann E; Shohat S; Loyter A
Antiviral Res; 2005 Apr; 66(1):67-78. PubMed ID: 15781134
[TBL] [Abstract][Full Text] [Related]
34. Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay.
Watkins JD; Beuerlein G; Pecht G; McFadden PR; Glaser SM; Huse WD
Anal Biochem; 1997 Nov; 253(1):37-45. PubMed ID: 9356139
[TBL] [Abstract][Full Text] [Related]
35. [Study of the interaction of the monoclonal antibody to human interleukin-2 and its Fab-fragment with synthetic peptides --interleukin-2 fragments by (1)H-NMR].
Balashova TA; Pashkov VS; Onoprienko LV; Mikhaleva II; Mareeva TIu; Petrova EE; Nesmeianov VA; Ivanov VT
Bioorg Khim; 1991 Nov; 17(11):1470-86. PubMed ID: 1811542
[TBL] [Abstract][Full Text] [Related]
36. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells.
Tünnemann G; Martin RM; Haupt S; Patsch C; Edenhofer F; Cardoso MC
FASEB J; 2006 Sep; 20(11):1775-84. PubMed ID: 16940149
[TBL] [Abstract][Full Text] [Related]
37. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus.
Vivès E; Brodin P; Lebleu B
J Biol Chem; 1997 Jun; 272(25):16010-7. PubMed ID: 9188504
[TBL] [Abstract][Full Text] [Related]
38. Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide.
Bhorade R; Weissleder R; Nakakoshi T; Moore A; Tung CH
Bioconjug Chem; 2000; 11(3):301-5. PubMed ID: 10821645
[TBL] [Abstract][Full Text] [Related]
39. Efflux of intracellular colchicine in lymphocytes with colchicine-specific Fab fragments.
Chappey ON; Niel E; Debray M; Wautier JL; Scherrmann JM
J Pharmacol Exp Ther; 1995 Sep; 274(3):1072-6. PubMed ID: 7562471
[TBL] [Abstract][Full Text] [Related]
40. A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)Tat neutralizes tetanus toxin inside chromaffin cells.
Stein S; Weiss A; Adermann K; Lazarovici P; Hochman J; Wellhöner H
FEBS Lett; 1999 Sep; 458(3):383-6. PubMed ID: 10570945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
